Scott Leftwich Purchases 125,000 Shares of Calidi Biotherapeutics (NYSE:CLDI) Stock

Calidi Biotherapeutics, Inc. (NYSE:CLDI) Director Scott Leftwich purchased 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 21st. The shares were acquired at an average price of $2.00 per share, for a total transaction of $250,000.00. Following the completion of the transaction, the director owned 130,650 shares in the company, valued at $261,300. The trade was a 2,212.39% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Calidi Biotherapeutics Trading Down 1.8%

Shares of CLDI opened at $1.67 on Thursday. The business’s fifty day moving average price is $5.25 and its two-hundred day moving average price is $6.66. Calidi Biotherapeutics, Inc. has a 52 week low of $1.54 and a 52 week high of $46.68.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in shares of Calidi Biotherapeutics in the 4th quarter valued at $38,000. Belpointe Asset Management LLC acquired a new position in shares of Calidi Biotherapeutics in the 1st quarter valued at $141,000. Millennium Management LLC lifted its stake in shares of Calidi Biotherapeutics by 35.5% in the 4th quarter. Millennium Management LLC now owns 136,137 shares of the company’s stock valued at $157,000 after purchasing an additional 35,637 shares during the period. Geode Capital Management LLC lifted its stake in shares of Calidi Biotherapeutics by 304.0% in the 4th quarter. Geode Capital Management LLC now owns 160,018 shares of the company’s stock valued at $184,000 after purchasing an additional 120,406 shares during the period. Finally, Armistice Capital LLC acquired a new position in shares of Calidi Biotherapeutics in the 1st quarter valued at $1,881,000. 12.53% of the stock is currently owned by institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.